Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Solid Tumor 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 139pembrolizumab 88Carboplatin 73Radiotherapy 71Cetuximab 69Docetaxel 58Paclitaxel 52Radiotherapy, Intensity-Modulated 43Fluorouracil 43Nivolumab 32Surgical Procedures, Operative 18Albumin-Bound Paclitaxel 15130-nm albumin-bound paclitaxel 15Radiation 14Drug Therapy 14tislelizumab 13Taxes 13durvalumab 12Magnetic Resonance Spectroscopy 12toripalimab 11camrelizumab 11Platinum 11Chemoradiotherapy 11Biopsy 11cemiplimab 10Radiosurgery 10Erlotinib Hydrochloride 10Capecitabine 10Specimen Handling 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Squamous Cell Carcinoma of Head and Neck × magrolimab × Clear all
NCT04854499 2025-11-19

ELEVATE HNSCC

Gilead Sciences

Phase 2 Terminated
193 enrolled 27 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
4 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡